Several recent studies have reported that FOXC1 overexpression is strongly correlated with poor survival in the patients of multiple cancers such as breast cancer, pancreatic ductal adenocarcinoma, non-small cell lung cancer, or hepatocellular carcinoma [6–11]. Here, FOXC1 is linked to breast cancer.